Diseases /

Core Binding Factor Acute Myeloid Leukemia

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis. [1]

Core binding factor acute myeloid leukemias most frequently harbor alterations in NRAS, KIT, ASXL1, TET2, and FLT3 [2].

Most Commonly Altered Genes in Core Binding Factor Acute Myeloid Leukemia

NRAS Mutation, KIT Mutation, KIT Exon 17 Mutation, ASXL1fs, and NRAS Exon 2 Mutation are the most common alterations in core binding factor acute myeloid leukemia [2].

Top Alterations in Core Binding Factor Acute Myeloid Leukemia

Clinical Trials

View Clinical Trials for Core Binding Factor Acute Myeloid Leukemia

Significant Genes in Core Binding Factor Acute Myeloid Leukemia

CBFB +

MYH11 +

RUNX1 +

RUNX1T1 +

Disease Details

Synonyms
CBF-AML
Parent(s)
Acute Myeloid Leukemia with Recurrent Genetic Abnormalities
Children
Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 and Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.